2023 – Innovative Therapies for Hereditary Ataxias

  • 2023 – Innovative Therapies for Hereditary Ataxias

    Code : GQ
    Organisator : Santé humaine (GQ )
    Year : 2023
    Duration : 2 years

    Génome Québec, Ataxia Canada and Muscular Dystrophy Canada are pleased to announce the launch of the opportunity “Innovative therapies for hereditary ataxias”. This one million dollars funding opportunity aims to bring together researchers from different disciplines to discover or develop innovative therapies that support the following objectives:

    • Addressing the needs of people living with a hereditary ataxia from the group of ataxias covered by Ataxia Canada. Under this request for applications, Muscular Dystrophy Canada aims to finance studies on Friedreich’s ataxia.
    • Supporting the discovery and development of novel therapies using omics approaches (including those to alter the function of one or several genes).
    • Encouraging multidisciplinary research in Quebec, to benefit research on hereditary ataxias.


    For more details on the competition requirements, please see the request for applications document below.


    Funding Overview

    Research teams will develop a research program with concrete activities and deliverables, enabling discovery or development of an innovative therapy for a hereditary ataxia.

    This program will finance projects with a total budget from $165,000 up to $330,000 each (no co-funding required).

    All applicants must submit their application through Génome Québec. The process will consist of a mandatory registration and an application (see below for the documents).


    The important dates and key steps of the application process for this funding opportunity are as follows:


    April 28, 2023

    Competition launch

    June 8, 2023

    Mandatory registration deadline: Please submit the registration form to:


    End of June, 2023

    Notice of eligibility 

    October 3, 2023

    Application submission deadline: Please submit your application (including the budget) to tia-ita@genomequebec.com

    End of November 2023

    Peer Review

    End of December 2023

    Notice of decision

    April 1, 2024

    Start of project


    Transfer of first installment to projects


    All applications must be submitted to Génome Québec. To obtain more details related to the initiative, please contact Annina Spilker, Manager of programs and strategic initiatives, by email at tia-ita@genomequebec.com.

    Full Application Form : this form will be available June 1, 2023 – please note that only teams having submitted an eligible registration will be invited to submit an application.